DSM Divests Biologics Plant; Focuses on Cell Technology

DSM says it has sold its biologic drugs plant at Montreal to AstraZeneca for an undisclosed sum. The Montreal facility was DSM’s only commercial manufacturing plant for biologic drugs. The company says it plans to focus its biologics activities on developing manufacturing technologies and services. Staal: Change of strategy for biologics. DSM says it mothballed the Montreal plant in December 2005 due to a lack of orders for products from the facility. DSM says it will book a “small profit” from the divestment but it declined to provide...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers